Case number 1:23-cv-00490
Teva Pharmaceuticals International GmbH et al v. BendaRx USA > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jul 2, 2024 | 75 | NOTICE OF SERVICE of BendaRx USA Corp.'s First Supplemental Responses to Plaintiffs' First Set of Requests for the Production of Documents and Things (Supplementing Responses to Request Nos. 33-39, 44, and 45) filed by BendaRx USA.(Metzler, Sara) (Entered: 07/02/2024) (2) |
| Jun 28, 2024 | 74 | NOTICE OF SERVICE of BendaRx USA Corp.'s Supplemental Response to Interrogatory No. 4 filed by BendaRx USA.(Metzler, Sara) (Entered: 06/28/2024) (2) |
| Jun 14, 2024 | 73 | Joint CLAIM Construction Chart, by Teva Pharmaceuticals International GmbH. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I)(Hoeschen, Nathan) Modified on 6/14/2024 (ceg). (Entered: 06/14/2024) (0) |
| Jun 7, 2024 | 72 | NOTICE OF SERVICE of BendaRx USA Corp.s Responses to Plaintiffs Second Set of Requests for the Production of Documents and Things filed by BendaRx USA.(Metzler, Sara) (Entered: 06/07/2024) (2) |
| May 29, 2024 | 70 | MOTION for Pro Hac Vice Appearance of Attorney Robert F. Hartsmith - filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH. (Hoeschen, Nathan) (Entered: 05/29/2024) (3) |
| May 29, 2024 | 71 | Pro Hac Vice Fee - Credit Card Payment received for Robert F. Hartsmith. ( re 70 MOTION for Pro Hac Vice Appearance of Attorney Robert F. Hartsmith )( Payment of $ 50, receipt number ADEDC-4418019).(Hoeschen, Nathan) (Entered: 05/29/2024) (0) |
| May 24, 2024 | 69 | NOTICE OF SERVICE of BendaRx USA Corp.s Initial Identification of Claim Terms/Phrases and Proposed Constructions filed by BendaRx USA.(Metzler, Sara) (Entered: 05/24/2024) (2) |
| May 17, 2024 | 68 | NOTICE OF SERVICE of Initial Invalidity Contentions filed by BendaRx USA.(Hunter, Travis) (Entered: 05/17/2024) (2) |
| May 14, 2024 | 67 | NOTICE OF SERVICE of Plaintiffs Teva Pharmaceutical International GmbH and Cephalon, Inc.'s Supplemental Initial Disclosures Pursuant to Rule 26(a)(1) of the Federal Rules of Civil Procedure and Paragraph 3 of the Delaware Default Standard for Discovery filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH.(Hoeschen, Nathan) (Entered: 05/14/2024) (2) |
| May 8, 2024 | 66 | NOTICE OF SERVICE of Plaintiffs' Second Set of Requests for Production to Defendant BendaRx USA Corp. filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH.(Hoeschen, Nathan) (Entered: 05/08/2024) (2) |
| May 7, 2024 | 65 | NOTICE OF SERVICE of BendaRx USA Corp.s Responses to Plaintiffs Second Set of Interrogatories filed by BendaRx USA.(Metzler, Sara) (Entered: 05/07/2024) (2) |
| May 1, 2024 | 64 | NOTICE requesting Clerk to remove Wei-Chih Hsu as co-counsel. Reason for request: Leaving the Firm. (Metzler, Sara) (Entered: 05/01/2024) (1) |
| Apr 22, 2024 | 62 | NOTICE OF SERVICE of 1. Plaintiffs' Initial Claim Charts; 2. Plaintiffs' Objections and Responses to Defendant BendaRx USA Corp's First Set of Interrogatories (Nos. 1 - 4); 3. Plaintiff Teva Pharmaceuticals International GmbH and Cephalon, LLC's Objections and Responses to Defendant BendaRx USA Corp.'s Second Set of Requests for Production (Nos. 5 - 83), filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH.(Keller, Karen) Modified on 4/22/2024 (ceg). (Entered: 04/22/2024) (2) |
| Apr 22, 2024 | 63 | NOTICE OF SERVICE of BendaRx USA Corp.'s Responses to Plaintiffs' First Set of Interrogatories filed by BendaRx USA.(Metzler, Sara) (Entered: 04/22/2024) (2) |
| Apr 19, 2024 | 61 | NOTICE OF SERVICE of Plaintiff Eagle Pharmaceuticals, Inc.'s Responses and Objections to Defendant's Second Set of Requests for Production of Documents and Things (Nos. 5-83) filed by Eagle Pharmaceuticals, Inc..(Joyce, Alexandra) (Entered: 04/19/2024) (3) |
| Apr 5, 2024 | 60 | NOTICE OF SERVICE of Plaintiffs' Second Set of Interrogatories to Defendant BendaRx USA Corp. filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH.(Hoeschen, Nathan) (Entered: 04/05/2024) (2) |
| Apr 3, 2024 | 57 | Pro Hac Vice Fee - Credit Card Payment received for Michelle Wang. ( re 56 MOTION for Pro Hac Vice Appearance of Attorney Michelle Wang )( Payment of $ 50, receipt number ADEDC-4376109).(Metzler, Sara) (Entered: 04/03/2024) (0) |
| Apr 3, 2024 | 58 | MOTION for Pro Hac Vice Appearance of Attorney Wei-Chih Hsu - filed by BendaRx USA. (Metzler, Sara) (Entered: 04/03/2024) (2) |
| Apr 3, 2024 | 59 | Pro Hac Vice Fee - Credit Card Payment received for Wei-Chih Hsu. ( re 58 MOTION for Pro Hac Vice Appearance of Attorney Wei-Chih Hsu )( Payment of $ 50, receipt number BDEDC-4376565).(Metzler, Sara) (Entered: 04/03/2024) (0) |
| Apr 2, 2024 | 56 | MOTION for Pro Hac Vice Appearance of Attorney Michelle Wang - filed by BendaRx USA. (Metzler, Sara) (Entered: 04/02/2024) (2) |
| Apr 1, 2024 | 55 | ANSWER to 50 Answer to Amended Complaint, Counterclaim [Plaintiffs' Answer to BendaRx's Counterclaims] by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH.(Hoeschen, Nathan) (Entered: 04/01/2024) (26) |
| Mar 25, 2024 | 52 | MOTION for Pro Hac Vice Appearance of Attorney Kelly A. Welsh - filed by Eagle Pharmaceuticals, Inc.. (Joyce, Alexandra) (Entered: 03/25/2024) (3) |
| Mar 25, 2024 | 53 | Pro Hac Vice Fee - Credit Card Payment received for Kelly A. Welsh. ( re 52 MOTION for Pro Hac Vice Appearance of Attorney Kelly A. Welsh )( Payment of $ 50, receipt number ADEDC-4369676).(Joyce, Alexandra) (Entered: 03/25/2024) (0) |
| Mar 25, 2024 | 54 | NOTICE OF SERVICE of (1) BendaRx USA Corp.s Second Set of Requests for Production to Plaintiffs (Nos. 5-83) and (2) BendaRx USA Corp.s First Set of Interrogatories to Plaintiffs (Nos. 1-4) filed by BendaRx USA.(Metzler, Sara) (Entered: 03/25/2024) (2) |
| Mar 22, 2024 | 51 | NOTICE OF SERVICE of Plaintiffs' First Set of Interrogatories to Defendant BendaRx USA Corp. filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH.(DiBenedetto, Emily) (Entered: 03/22/2024) (2) |
| Mar 8, 2024 | 50 | ANSWER to 46 Amended Complaint, COUNTERCLAIM against Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH by BendaRx USA. (Metzler, Sara) Modified on 3/11/2024 (ceg). (Entered: 03/08/2024) (30) |
| Feb 29, 2024 | 49 | NOTICE OF SERVICE of BendaRx Corp.'s Responses to Plaintiffs First Set of Requests to Defendants for the Production of Documents and Things filed by BendaRx USA.(Metzler, Sara) (Entered: 02/29/2024) (2) |
| Feb 26, 2024 | 47 | NOTICE OF SERVICE of Plaintiff Eagle Pharmaceuticals, Inc.'s Responses and Objections to Defendant's First Set of Request for Production of Documents and Things (Nos. 1-4) filed by Eagle Pharmaceuticals, Inc..(Joyce, Alexandra) (Entered: 02/26/2024) (3) |
| Feb 26, 2024 | 48 | NOTICE OF SERVICE of Plaintiff Teva Pharmaceuticals International and Cephalon, LLC's Objections and Responses to Defendant BendaRx USA Corp.'s First Set of Requests for Production (Nos. 1-4) filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH.(DiBenedetto, Emily) (Entered: 02/26/2024) (2) |
| Feb 23, 2024 | 46 | Amended Complaint* (1) |
| Feb 22, 2024 | 44 | NOTICE OF SERVICE of (1) Plaintiff Eagle Pharmaceuticals, Inc.'s Rule 26(a)(1) Initial Disclosures and (2) Plaintiff Eagle Pharmaceuticals, Inc.'s Initial Disclosures Pursuant to Delaware Default Standard for Discovery filed by Eagle Pharmaceuticals, Inc..(Joyce, Alexandra) (Entered: 02/22/2024) (3) |
| Feb 22, 2024 | 45 | NOTICE OF SERVICE of Plaintiffs Teva Pharmaceutical International GmbH and Cephalon, Inc.'s Initial Disclosures Pursuant to Rule 26(a)(1) of the Federal Rules of Civil Procedure and Paragraph 3 of the Delaware Default Standard for Discovery filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH.(DiBenedetto, Emily) (Entered: 02/22/2024) (2) |
| Feb 21, 2024 | 42 | NOTICE OF SERVICE of Plaintiffs' Initial Identification of Asserted Patents and Accused Products filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH.(Hoeschen, Nathan) (Entered: 02/21/2024) (2) |
| Feb 21, 2024 | 43 | NOTICE OF SERVICE of (1) Defendant's Rule 26(a)(1) Initial Disclosures and (2) Defendant's Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery filed by BendaRx USA.(Metzler, Sara) (Entered: 02/21/2024) (2) |
| Feb 15, 2024 | 41 | NOTICE of Appearance by Sara M. Metzler on behalf of BendaRx USA (Metzler, Sara) (Entered: 02/15/2024) (1) |
| Feb 14, 2024 | 40 | SCHEDULING ORDER: Joinder of Parties due by 11/15/2024. Amended Pleadings due by 11/15/2024. Fact Discovery completed by 11/8/2024. Expert Discovery due by 4/11/2025. Status Report due by 9/27/2024. Joint Claim Construction Brief due by 9/20/2024. A Markman Hearing is set for 10/23/2024 at 10:00 AM in Courtroom 6D before Judge Jennifer L. Hall. Proposed Pretrial Order due by 5/5/2025. A Pretrial Conference is set for 5/12/2025 at 03:00 PM in Courtroom 6D before Judge Jennifer L. Hall. A 5-day Jury Trial is set for 5/19/2025 at 09:30 AM in Courtroom 6D before Judge Jennifer L. Hall. (*See Order for details). Signed by Judge Jennifer L. Hall on 2/14/2024. (ceg) (Entered: 02/14/2024) (15) |
| Feb 13, 2024 | 38 | NOTICE of Withdrawal of Nathalie A. Freeman by BendaRx USA (Freeman, Nathalie) (Entered: 02/13/2024) (1) |
| Feb 13, 2024 | 39 | PROPOSED Scheduling Order by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (Attachments: # 1 Letter to The Honorable Jennifer L. Hall from Emily S. DiBenedetto regarding the parties Proposed Scheduling Order)(DiBenedetto, Emily) Modified on 2/14/2024 (ceg). (Entered: 02/13/2024) (0) |
| Feb 9, 2024 | 37 | SO ORDERED, re (31 in 1:23-cv-00633-JLH, 35 in 1:23-cv-00490-JLH) Stipulation and Order substituting Defendant BendaRx USA for BendaRx Canada. These actions, C.A. 23-490 and C.A. 23-633, shall be CONSOLIDATED for all purposes. The pending motions to dismiss, C.A. 23-490, D.I. 12 and C.A. 23-633, D.I. 10, are DENIED as moot. Signed by Judge Jennifer L. Hall on 2/9/2024. Associated Cases: 1:23-cv-00490-JLH, 1:23-cv-00633-JLH(ceg) (Entered: 02/09/2024) (6) |
| Feb 8, 2024 | 36 | SO ORDERED, re (34 in 1:23-cv-00490-JLH; 30 in 1:23-cv-00633-JLH) Stipulation and Order to Extend Time for the parties to comply with the Court's Order to February 9, 2024. Signed by Judge Jennifer L. Hall on 2/8/2024. Associated Cases: 1:23-cv-00490-JLH, 1:23-cv-00633-JLH(ceg) (Entered: 02/08/2024) (5) |
| Feb 7, 2024 | 35 | STIPULATION and [Proposed] Order regarding substitution of BendaRx USA for BendaRx Canada by Teva Pharmaceuticals International GmbH. (DiBenedetto, Emily) (Entered: 02/07/2024) (6) |
| Feb 2, 2024 | 34 | STIPULATION and [Proposed] Order to Extend Time for the parties to comply with the Court's order (C.A. 23-633, D.I. 28) to February 9, 2024 - filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH. (DiBenedetto, Emily) Modified on 2/5/2024 (ceg). (Entered: 02/02/2024) (5) |
| Jan 30, 2024 | 33 | NOTICE OF SERVICE of Plaintiffs' First Set of Requests for Production to Defendant BendaRx Corp. filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH.(Hoeschen, Nathan) (Entered: 01/30/2024) (2) |
| Jan 25, 2024 | 30 | MOTION for Pro Hac Vice Appearance of Attorney David I. Berl, Adam D. Harber, Elise M. Baumgarten, and Kathryn Larkin - filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH. (DiBenedetto, Emily) (Entered: 01/25/2024) (7) |
| Jan 25, 2024 | 31 | ORAL ORDER REFERRING MOTION: IT IS HEREBY ORDERED that the Motion to Dismiss for Failure to State a Claim (D.I. 12 ) is now REFERRED to Magistrate Judge Christopher J. Burke. The Court requests that the parties consider consenting to the jurisdiction of Judge Burke to resolve the pending motion; accordingly, IT IS FURTHER ORDERED that, on or before February 2, 2024, the parties shall either (1) submit to the Clerk of Court an executed Form AO 85A Notice, Consent, and Reference of a Dispositive Motion to a Magistrate Judge that sets forth the parties' consent to consideration of the pending motion by a Magistrate Judge; or (2) file a joint letter indicating that both parties do not so consent. The letter should not indicate which party or parties did not consent. Ordered by Judge Jennifer L. Hall on 1/25/2024. (ceg) (Entered: 01/25/2024) (0) |
| Jan 25, 2024 | 32 | Pro Hac Vice Fee - Credit Card Payment received for David I. Berl, Adam D. Harber, Elise M. Baumgarten, and Kathryn Larkin. ( re 30 MOTION for Pro Hac Vice Appearance of Attorney David I. Berl, Adam D. Harber, Elise M. Baumgarten, and Kathryn Larkin )( Payment of $ 200, receipt number ADEDC-4322773).(DiBenedetto, Emily) (Entered: 01/25/2024) (0) |
| Jan 22, 2024 | 29 | SO ORDERED, re 28 Stipulation and Order regarding dismissal of Counts XVII, XVIII, XIX, and XX of Plaintiffs' Complaints. Signed by Judge Jennifer L. Hall on 1/22/2024. (ceg) (Entered: 01/22/2024) (6) |
| Jan 19, 2024 | 28 | STIPULATION and [Proposed] Order regarding dismissal of Counts XVII, XVIII, XIX, and XX of Plaintiffs' Complaints by Cephalon, LLC, Teva Pharmaceuticals International GmbH. (DiBenedetto, Emily) (Entered: 01/19/2024) (6) |
| Aug 22, 2023 | 27 | NOTICE of Subsequent Authority regarding BendaRx Corp.'s Motions to Dismiss by Cephalon, LLC, Teva Pharmaceuticals International GmbH re (12 in 1:23-cv-00490-CFC) MOTION to Dismiss for Failure to State a Claim , (10 in 1:23-cv-00633-CFC) MOTION to Dismiss for Failure to State a Claim (Attachments: # 1 Exhibit 1)(Hoeschen, Nathan) (Entered: 08/22/2023) (0) |
| Aug 3, 2023 | 26 | AFFIDAVIT of Mailing dated 12/4/13, of Summons, First Amended Complaint, French Translation of the First Amended Complaint, Civil Cover Sheet, Patent Report, 7.1 Statement, and MAG sent via Registered Mail pursuant to Rule 4(f)(2)(C)(ii) to BendaRx Corp. (jfm) (Entered: 08/03/2023) (3) |
| Aug 2, 2023 | 25 | PRAECIPE filed by Emily DiBenedetto on behalf of Cephalon, LLC, Teva Pharmaceuticals International GmbH requesting Clerk to issue address and send via United States Postal Service international registered mail, return receipt requested, one copy of the service package (Service Package) in the above referenced case to defendant BendaRx Corp. (Attachments: # 1 Declaration of Emily S. DiBenedetto)(DiBenedetto, Emily) (Main Document 25 replaced on 8/3/2023) (smg). (Entered: 08/02/2023) (0) |
| Jul 21, 2023 | 24 | REDACTED VERSION of 20 Exhibit to a Document by BendaRx Corp.. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Hunter, Travis) (Entered: 07/21/2023) (0) |
| Jul 20, 2023 | 22 | PROPOSED ORDER -- Protective Order (corrected version) by Cephalon, LLC, Teva Pharmaceuticals International GmbH. (Keller, Karen) (Entered: 07/20/2023) (30) |
| Jul 20, 2023 | 23 | PROTECTIVE ORDER. Signed by Judge Colm F. Connolly on 7/20/2023. Associated Cases: 1:23-cv-00490-CFC, 1:23-cv-00633-CFC(kmd) (Entered: 07/20/2023) (30) |
| Jul 19, 2023 | 21 | PROPOSED ORDER -- Protective Order by Cephalon, LLC, Teva Pharmaceuticals International GmbH. (Keller, Karen) (Entered: 07/19/2023) (30) |
| Jul 14, 2023 | 17 | MOTION for Pro Hac Vice Appearance of Attorney Anne Elise Herold Li, Mark H. Remus, Shannon Lentz, Karla I. Arias and Kassidy Schmitz - filed by BendaRx Corp.. (Freeman, Nathalie) (Entered: 07/14/2023) (7) |
| Jul 14, 2023 | 18 | REDACTED VERSION of 16 Exhibit to a Document by Cephalon, LLC, Teva Pharmaceuticals International GmbH. (DiBenedetto, Emily) (Entered: 07/14/2023) (16) |
| Jul 14, 2023 | 19 | REPLY BRIEF re 12 MOTION to Dismiss for Failure to State a Claim filed by BendaRx Corp.. (Attachments: # 1 Certificate of Compliance, # 2 Exhibit C)(Hunter, Travis) (Entered: 07/14/2023) (0) |
| Jul 14, 2023 | 20 | [SEALED] EXHIBIT re 19 Reply Brief Exhibits A and B by BendaRx Corp.. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Hunter, Travis) (Entered: 07/14/2023) (0) |
| Jul 7, 2023 | 15 | ANSWERING BRIEF in Opposition re 12 MOTION to Dismiss for Failure to State a Claim filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH.Reply Brief due date per Local Rules is 7/14/2023. (Attachments: # 1 Exhibit 3)(Hoeschen, Nathan) (Entered: 07/07/2023) (0) |
| Jul 7, 2023 | 16 | [SEALED] EXHIBIT re 15 Answering Brief in Opposition, (Exhibits 1-2) by Cephalon, LLC, Teva Pharmaceuticals International GmbH. (Hoeschen, Nathan) (Entered: 07/07/2023) (0) |
| Jun 26, 2023 | N/A | CORRECTING ENTRY: Documents to D.I. 12 replaced per Counsels request to reflect the correct case number. (jdb) (Entered: 06/26/2023) (0) |
| Jun 23, 2023 | 12 | MOTION to Dismiss for Failure to State a Claim - filed by BendaRx Corp. (Attachments: # 1 Text of Proposed Order, # 2 7.1 Corporate Disclosure Statement)(Hunter, Travis) (Main Document 12, Attachment 1, and Attachment 2 replaced on 6/26/2023) (jdb). (Entered: 06/23/2023) (Main Document) (2) |
| Jun 23, 2023 | 13 | OPENING BRIEF in Support re 12 MOTION to Dismiss for Failure to State a Claim filed by BendaRx Corp..Answering Brief/Response due date per Local Rules is 7/7/2023. (Attachments: # 1 Certificate of Compliance)(Hunter, Travis) (Entered: 06/23/2023) (Main Document) (25) |
| Jun 23, 2023 | 14 | NOTICE of Appearance by Nathalie Anne Freeman on behalf of BendaRx Corp. (Freeman, Nathalie) (Entered: 06/23/2023) (1) |
| Jun 23, 2023 | 13 | OPENING BRIEF in Support re 12 MOTION to Dismiss for Failure to State a Claim filed by BendaRx Corp..Answering Brief/Response due date per Local Rules is 7/7/2023. (Attachments: # 1 Certificate of Compliance)(Hunter, Travis) (Entered: 06/23/2023) (Certificate of Compliance) (1) |
| Jun 23, 2023 | 12 | MOTION to Dismiss for Failure to State a Claim - filed by BendaRx Corp. (Attachments: # 1 Text of Proposed Order, # 2 7.1 Corporate Disclosure Statement)(Hunter, Travis) (Main Document 12, Attachment 1, and Attachment 2 replaced on 6/26/2023) (jdb). (Entered: 06/23/2023) (Text of Proposed Order) (1) |
| Jun 23, 2023 | 12 | MOTION to Dismiss for Failure to State a Claim - filed by BendaRx Corp. (Attachments: # 1 Text of Proposed Order, # 2 7.1 Corporate Disclosure Statement)(Hunter, Travis) (Main Document 12, Attachment 1, and Attachment 2 replaced on 6/26/2023) (jdb). (Entered: 06/23/2023) (7.1 Corporate Disclosure Statement) (2) |
| May 16, 2023 | N/A | SO ORDERED, re 11 MOTION for Pro Hac Vice Appearance of Attorney Kenneth G. Schuler, Marc N. Zubick, Alex Grabowski, and Daniel G. Brown, filed by Eagle Pharmaceuticals, Inc. Ordered by Judge Colm F. Connolly on 5/16/2023. (kmd) (Entered: 05/16/2023) (0) |
| May 16, 2023 | N/A | Pro Hac Vice Attorney Alex M. Grabowski for Eagle Pharmaceuticals, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) (Entered: 05/16/2023) (0) |
| May 15, 2023 | 11 | MOTION for Pro Hac Vice Appearance of Attorney Kenneth G. Schuler, Marc N. Zubick, Alex Grabowski, and Daniel G. Brown - filed by Eagle Pharmaceuticals, Inc.. (Joyce, Alexandra) (Entered: 05/15/2023) (6) |
| May 10, 2023 | N/A | Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. (rjb) (Entered: 05/10/2023) (0) |
| May 10, 2023 | 9 | MOTION for Pro Hac Vice Appearance of Attorney Ben Picozzi - filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH. (DiBenedetto, Emily) (Entered: 05/10/2023) (4) |
| May 10, 2023 | N/A | SO ORDERED, re 9 MOTION for Pro Hac Vice Appearance of Attorney Ben Picozzi, filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH. Ordered by Judge Colm F. Connolly on 5/10/2023. (kmd) (Entered: 05/10/2023) (0) |
| May 10, 2023 | N/A | Pro Hac Vice Attorney Ben V. Picozzi for Cephalon, LLC and Teva Pharmaceuticals International GmbH added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (jdb) (Entered: 05/10/2023) (0) |
| May 10, 2023 | 10 | STANDING ORDER REGARDING BRIEFING IN ALL CASES (nmf) (Entered: 05/10/2023) (2) |
| May 5, 2023 | 7 | Disclosure Statement pursuant to Rule 7.1: identifying Other Affiliate Teva Ltd., Other Affiliate Capital Research Global Investors for Teva Pharmaceuticals International GmbH; Other Affiliate Teva Ltd., Other Affiliate Cupric Holding Co. LLC for Cephalon, LLC filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH. (vfm) (Entered: 05/05/2023) (3) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Main Document) (30) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit A) (26) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit B) (30) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit C) (28) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit D) (30) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit E) (29) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit F) (30) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit G) (28) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit H) (30) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit I) (18) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit J) (30) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit K) (28) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit L) (22) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit M) (2) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit N) (2) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit O) (2) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit P) (3) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit Q) (2) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit R) (5) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit S) (9) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit T) (4) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit U) (14) |
| May 5, 2023 | 8 | First AMENDED COMPLAINT against BendaRx Corp.- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V)(DiBenedetto, Emily) (Entered: 05/05/2023) (Exhibit V) (7) |
| May 4, 2023 | 1 | COMPLAINT for ANDA/PATENT INFRINGEMENT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4128124.) - filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Civil Cover Sheet) (vfm) (Entered: 05/04/2023) (Main Document) (30) |
| May 4, 2023 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (vfm) (Entered: 05/04/2023) (3) |
| May 4, 2023 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 03/23/2023. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 9/23/2025. (vfm) (Entered: 05/04/2023) (2) |
| May 4, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) See Attached. (Attachments: # 1 Patent/Trademark Report Part 2, # 2 Patent/Trademark Report Part 3) (vfm) (Entered: 05/04/2023) (Main Document) (1) |
| May 4, 2023 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Other Affiliate Janus Henderson Group PLC, Other Affiliate BlackRock Institutional Trust Company, N.A. for Eagle Pharmaceuticals, Inc. filed by Cephalon, LLC, Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (vfm) (Entered: 05/04/2023) (1) |
| May 4, 2023 | N/A | DEFICIENCY NOTICE issued by the Court to Plaintiff: Pursuant to Fed. R. Civ. P. 7.1 (b)(1), A party must: (1) file the disclosure statement with its first appearance, pleading, petition, motion, response, or other request addressed to the court. Counsel is requested to supplement the docket with an appropriate Rule 7.1 Disclosure Statement. (vfm) (Entered: 05/04/2023) (0) |
| May 4, 2023 | 6 | Summons Issued as to BendaRx Corp. on 5/4/2023. (vfm) (Entered: 05/04/2023) (2) |
| May 4, 2023 | 1 | COMPLAINT for ANDA/PATENT INFRINGEMENT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4128124.) - filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Civil Cover Sheet) (vfm) (Entered: 05/04/2023) (Exhibit A) (26) |
| May 4, 2023 | 1 | COMPLAINT for ANDA/PATENT INFRINGEMENT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4128124.) - filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Civil Cover Sheet) (vfm) (Entered: 05/04/2023) (Exhibit B) (30) |
| May 4, 2023 | 1 | COMPLAINT for ANDA/PATENT INFRINGEMENT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4128124.) - filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Civil Cover Sheet) (vfm) (Entered: 05/04/2023) (Exhibit C) (28) |
| May 4, 2023 | 1 | COMPLAINT for ANDA/PATENT INFRINGEMENT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4128124.) - filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Civil Cover Sheet) (vfm) (Entered: 05/04/2023) (Exhibit D) (30) |
| May 4, 2023 | 1 | COMPLAINT for ANDA/PATENT INFRINGEMENT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4128124.) - filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Civil Cover Sheet) (vfm) (Entered: 05/04/2023) (Exhibit E) (29) |
| May 4, 2023 | 1 | COMPLAINT for ANDA/PATENT INFRINGEMENT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4128124.) - filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Civil Cover Sheet) (vfm) (Entered: 05/04/2023) (Exhibit F) (30) |
| May 4, 2023 | 1 | COMPLAINT for ANDA/PATENT INFRINGEMENT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4128124.) - filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Civil Cover Sheet) (vfm) (Entered: 05/04/2023) (Exhibit G) (28) |
| May 4, 2023 | 1 | COMPLAINT for ANDA/PATENT INFRINGEMENT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4128124.) - filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Civil Cover Sheet) (vfm) (Entered: 05/04/2023) (Exhibit H) (30) |
| May 4, 2023 | 1 | COMPLAINT for ANDA/PATENT INFRINGEMENT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4128124.) - filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Civil Cover Sheet) (vfm) (Entered: 05/04/2023) (Exhibit I) (18) |
| May 4, 2023 | 1 | COMPLAINT for ANDA/PATENT INFRINGEMENT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4128124.) - filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Civil Cover Sheet) (vfm) (Entered: 05/04/2023) (Exhibit J) (30) |
| May 4, 2023 | 1 | COMPLAINT for ANDA/PATENT INFRINGEMENT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4128124.) - filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Civil Cover Sheet) (vfm) (Entered: 05/04/2023) (Exhibit K) (28) |
| May 4, 2023 | 1 | COMPLAINT for ANDA/PATENT INFRINGEMENT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4128124.) - filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Civil Cover Sheet) (vfm) (Entered: 05/04/2023) (Exhibit L) (22) |
| May 4, 2023 | 1 | COMPLAINT for ANDA/PATENT INFRINGEMENT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4128124.) - filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Civil Cover Sheet) (vfm) (Entered: 05/04/2023) (Exhibit M) (2) |
| May 4, 2023 | 1 | COMPLAINT for ANDA/PATENT INFRINGEMENT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4128124.) - filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Civil Cover Sheet) (vfm) (Entered: 05/04/2023) (Exhibit N) (2) |
| May 4, 2023 | 1 | COMPLAINT for ANDA/PATENT INFRINGEMENT filed against BendaRx Corp. ( Filing fee $ 402, receipt number ADEDC-4128124.) - filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Civil Cover Sheet) (vfm) (Entered: 05/04/2023) (Civil Cover Sheet) (3) |
| May 4, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) See Attached. (Attachments: # 1 Patent/Trademark Report Part 2, # 2 Patent/Trademark Report Part 3) (vfm) (Entered: 05/04/2023) (Patent/Trademark Report Part 2) (1) |
| May 4, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) See Attached. (Attachments: # 1 Patent/Trademark Report Part 2, # 2 Patent/Trademark Report Part 3) (vfm) (Entered: 05/04/2023) (Patent/Trademark Report Part 3) (1) |
